Evonik's Solo Flight: RAG-Stiftung's Sell-Down Plan Meets a Sharper Earnings Story
Published on 11/20/2026 at 14:41 | Editorial boerse-global.deEvonik's largest shareholder is in no hurry to abandon ship — but it does intend to shrink its stake. The RAG-Stiftung confirmed today, according to media reports, that it will keep whittling down its holding toward a target of 25.1%. For investors, that raises a question that has nothing to do with takeover speculation: can the market absorb further blocks of stock without the share price buckling?
The answer hinges less on the destination than on the pace. A target percentage describes an endpoint; it says nothing about how many shares change hands in any single move. Demand spread across several tranches is a different proposition from a larger block that must find buyers all at once.
Rettig's Clean Slate
The foundation's plan is a separate matter from BASF's abandoned approach. The Ludwigshafen giant walked away yesterday after Evonik turned down two non-binding cash offers, and it did not leave quietly: BASF made clear that Evonik's standalone prospects and the risks attached to them did not justify a higher valuation. It put no figure on those risks.
Interim chief Claus Rettig, speaking to Reuters, framed the withdrawal as a relief for the workforce — a removed uncertainty that lets Evonik concentrate on its own development. The foundation, for its part, is sticking to its reduction target even with no higher bid on the table.
The stock's trajectory tells its own story. Evonik hit a 52-week high of EUR 22.52 on 18 November, closed yesterday at EUR 18.30 and was trading at EUR 18.17 today. At EUR 18.26, Jefferies analyst Priyanka Patel's EUR 21 price target — reaffirmed yesterday after BASF's exit — sits above the market, though she kept her rating at "Hold." That target is a view on the equity, not a guide to the terms on which the foundation might place stock. Size and demand for the next tranche would say far more about what comes next.
Should investors sell immediately? Or is it worth buying Evonik?
Two Signals Investors Should Not Confuse
In the best case, the foundation finds enough buyers for each step without meaningful price concessions, and a lower stake need not translate into sustained pressure on the shares. Investors could then weight Evonik's operating progress more heavily than the prospect of further selldowns.
The opposite scenario is a larger tranche into thin demand. If the foundation had to sweeten the price materially, expectations for the terms of subsequent steps would sour — and even operational progress would not offset that near-term risk. A smooth ownership transfer, by contrast, would be no evidence of better business prospects. Anyone valuing the stock after the takeover episode should keep the two apart: buyers' willingness to absorb a stake sale, and Evonik's progress in expanding production. One can move the price without changing the other.
A 40% Earnings Leap — and a EUR 53 Million Loss
Strip away the M&A noise and the operating picture is brighter. Adjusted EBITDA from continuing operations came in at roughly EUR 630 million in the third quarter, against just under EUR 450 million a year earlier — a gain of about 40%. Evonik has sharpened its full-year guidance accordingly: adjusted EBITDA for 2026 should land in the upper half of a EUR 2.0 billion to EUR 2.2 billion range. In 2025 the figure was just under EUR 1.9 billion.
The bottom line was less flattering. The quarter closed with a loss of EUR 53 million, an improvement on EUR 106 million a year before, but a loss nonetheless. A hefty chunk of that came from structural costs of just over EUR 310 million booked in connection with an expanded restructuring programme — roughly half the quarter's adjusted EBITDA.
Two questions hang over the standalone story. First, how durable is the earnings jump? Evonik attributes the increase mainly to pricing and expects that tailwind to fade. Profit driven by higher prices can erode faster than profit driven by volume or permanently lower costs, and a single strong quarter cannot show how much survives once pricing stops helping. For the full year the company is steering toward the upper half of its range; even the midpoint of EUR 2.1 billion would be about 12% above the prior-year figure.
Second, the restructuring is not fully mapped out. The programme's second phase envisages a further 3,200 job cuts worldwide between 2027 and 2029, around 2,150 of them in Germany. The detailed measures are still being drafted.
Evonik at a turning point? This analysis reveals what investors need to know now.
Lafayette Is the Date That Matters
Operationally, mid-2027 is the checkpoint: the Lipid Innovation Center in Lafayette, Indiana, is due to reach full production capacity by then. If the ramp-up goes to plan, Evonik will have a concrete achievement in its standalone development to show for itself; a delay would push that proof further out.
Whether the stake reduction weighs on the shares, however, will be settled by demand when the foundation makes its next move — not by the remaining percentage. A well-absorbed tranche would leave the lower holding no reason in itself for lasting pressure. A larger step taken only with deep price concessions would make the sale risk the dominant consideration for investors. When the foundation does act, its size and terms will matter more than the headline target.
Evonik reports full-year 2026 results on 4 March 2027. At least EUR 2.1 billion in adjusted EBITDA would confirm the operating strength; it would say nothing yet about whether the restructuring ultimately succeeds. The company aims to have the detailed measures worked out by the end of 2026 — the first real gauge of how far preparations for implementation have progressed.
Ad
Evonik Stock: New Analysis - 20 November
Fresh Evonik information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
